


# TRANSMITTAL FORM



Application Number: 10/520,408 ✓  
 Filing Date: January 3, 2005  
 First Named Inventor: Thomas P. Quinn  
 Art Unit: Unknown  
 Examiner Name: Unknown  
 Attorney Docket Number: UVMO:023US

Total Number of Pages in this Submission : \_\_\_\_\_

## ENCLOSURES (check all that apply)

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input checked="" type="checkbox"/> Form PTO-1449<br><input checked="" type="checkbox"/> References <u>C1-C6 &amp; C9-C16</u><br><input type="checkbox"/> Certified Copy of Priority Documents<br><input type="checkbox"/> Reply to Missing Parts/Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts/Requirements<br><input type="checkbox"/> Declaration(s) _____<br><input type="checkbox"/> Copy of Notice of Missing Parts/Requirements | <input type="checkbox"/> Drawings(s) _____<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address<br><input type="checkbox"/> Statement under 37 CFR §3.73(b)<br><input type="checkbox"/> Designation of Patent Practitioners<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)<br><input type="checkbox"/> Check in the amount of \$<br><input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted<br>Deposit account number: <u>50-1212/UVMO:023US</u><br><input type="checkbox"/> Sequence Statement<br><input type="checkbox"/> Paper Copy of Sequence Listing<br><input type="checkbox"/> Computer Readable Form (CRF)<br><input checked="" type="checkbox"/> Postcard<br><input type="checkbox"/> _____<br><input type="checkbox"/> _____ |
|--|---|--|

Remarks:


## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski, L.L.P.	Customer Number	32425
Signature			
Printed Name	Steven L. Highlander	Reg. No.	37,642
Date	August 26, 2005		

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or Printed Name	Steven L. Highlander	Date	August 26, 2005



**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Thomas P. Quinn et al.

Serial No.: 10/520,408


Filed: January 3, 2005

For: Erb-2 RECEPTOR TARGETING PEPTIDE

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UVMO:023US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
August 26, 2005	
Date	Steven L. Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ UVMO:023US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,




Steven D. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: August 26, 2005

Form PTO-1449 (modified)

Atty. Docket No.  
UVMO:023USSerial No.  
10/520,408

List of Patents and Publications for Applicant's

Applicant

INFORMATION DISCLOSURE STATEMENT

Thomas P. Quinn  
Natalia G. Karasseva

(Use several sheets if necessary)

Filing Date:  
January 3, 2005Group:  
UnknownU.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1***U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C1	Alimandi <i>et al.</i> "Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors", <i>EMBO J</i> , 16(18):5608-5617, 1997.
	C2	Ballinger <i>et al.</i> , "Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display", <i>J Biol. Chem.</i> , 273(19): 11675-11684, 1998.
	C3	Baselga <i>et al.</i> , "Recombinant Humanized Anti-HER2 Antibody (Herceptin <sup>TM</sup> ) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts", <i>Cancer Res.</i> , 58:2825-2831, 1998.
	C4	Devlin <i>et al.</i> , "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", <i>Science</i> , 249:404-406, 1990.
	C5	Disis <i>et al.</i> , "Generation of Immunity to the HER-2/ <i>neu</i> Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine", <i>Clin. Cancer Res.</i> , 5(6):1289-1297, 1999.
	C6	Giebel <i>et al.</i> , "Screening of Cyclic Peptide Phage Libraries Identifies Ligands That Bind Streptavidin with High Affinities" <i>Biochemistry</i> , 34:15430-15435, 1995.
	C9	Jones <i>et al.</i> , "Binding Interaction of the Heregulin $\beta$ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis", <i>J. Biol. Chem.</i> , 273(9):11667-11674, 1998.
	C10	Kay <i>et al.</i> , "An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets", <i>Gene</i> 128:59-65, 1993.

25514576.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UVMO:023US	Serial No. 10/520,408
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thomas P. Quinn Natalia G. Karasova	
		Filing Date: January 3, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	McInnes and Sykes, "Growth Factor Receptors: Structure, Mechanism, and Drug Discovery", <i>Biopolymers</i> , 43(5):339-366, 1997.
	C12	Oldenburg <i>et al.</i> , "Peptide ligands for a sugar-binding protein isolated from a random peptide library", <i>Proc. Natl. Acad. Sci., USA</i> , 89:5393-5397, 1992.
	C13	Piccart, Perry (Ed.), American Soc. Clinical Oncology, Alexandria, VA, Integration of New Therapies Into Management of Metastatic Breast Cancer: A Focus on Chemotherapy, Treatment Selection Through Use of Molecular Markers, and Newly Developed Biologic Therapies in Late Clinical Development. "In: <i>American Society of Clinical Oncology Educational Book</i> ", 1999.
	C14	Weiner <i>et al.</i> , "Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FeyRIII" <i>Cancer Res.</i> , 55(20):4586-4593, 1995.
	C15	Wiechen <i>et al.</i> , "C-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of p185 <sup>c-erbB-2</sup> overexpressing ovarian carcinoma cells" <i>Int. J. Cancer</i> 63(4):604-608, 1995.
	C16	Wrighton <i>et al.</i> , "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin" <i>Science</i> 273, 458-463, 1996.

25514576.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.